Sertindole

Sertindole
Clinical data
Trade names	Serdolect, Serlect
AHFS/Drugs.com	International Drug Names
Pregnancy; category	AU: C; ;
Routes of; administration	By mouth
ATC code	N05AE03 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	75%
Protein binding	99.5%
Metabolism	Liver (mostly via CYP2D6 and CYP3A4)
Elimination half-life	3 days
Excretion	Faecal (the majority), Kidney (4% metabolites; 1% unchanged)
Identifiers
	IUPAC name 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one;
CAS Number	106516-24-9 ;
PubChem CID	60149;
IUPHAR/BPS	98;
DrugBank	DB06144 ;
ChemSpider	54229 ;
UNII	GVV4Z879SP;
KEGG	D00561 ;
ChEBI	CHEBI:9122 ;
ChEMBL	ChEMBL12713 ;
CompTox Dashboard (EPA)	DTXSID6048967 ;
ECHA InfoCard	100.162.562
Chemical and physical data
Formula	C24H26ClFN4O
Molar mass	440.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1)n3c2ccc(Cl)cc2c(c3)C5CCN(CCN4C(=O)NCC4)CC5;
	InChI InChI=1S/C24H26ClFN4O/c25-18-1-6-23-21(15-18)22(16-30(23)20-4-2-19(26)3-5-20)17-7-10-28(11-8-17)13-14-29-12-9-27-24(29)31/h1-6,15-17H,7-14H2,(H,27,31) ; Key:GZKLJWGUPQBVJQ-UHFFFAOYSA-N ;
	(verify)

Sertindole, sold under the brand name Serdolect among others, is an antipsychotic medication. Sertindole was developed by the Danish pharmaceutical company Lundbeck and marketed under license by Abbott Labs. Like other atypical antipsychotics, it has activity at dopamine and serotonin receptors in the brain. It is used in the treatment of schizophrenia. It is classified chemically as a phenylindole derivative.

Sertindole is not approved for use in the United States and was discontinued in Australia in January 2014.^{[citation needed]}

^ ^a ^b Karamatskos E, Lambert M, Mulert C, Naber D (November 2012). "Drug safety and efficacy evaluation of sertindole for schizophrenia". Expert Opinion on Drug Safety. 11 (6): 1047–62. doi:10.1517/14740338.2012.726984. PMID 22992213. S2CID 11339387.
^ ^a ^b ^c Cite error: The named reference TGA was invoked but never defined (see the help page).
^ Juruena MF, de Sena EP, de Oliveira IR (May 2011). "Sertindole in the management of schizophrenia". Journal of Central Nervous System Disease. 3: 75–85. doi:10.4137/JCNSD.S5729. PMC 3663609. PMID 23861640.

[Rev-1] Karamatskos E, Lambert M, Mulert C, Naber D (November 2012). "Drug safety and efficacy evaluation of sertindole for schizophrenia". Expert Opinion on Drug Safety. 11 (6): 1047–62. doi:10.1517/14740338.2012.726984. PMID 22992213. S2CID 11339387.

[TGA-2] Cite error: The named reference TGA was invoked but never defined (see the help page).

[Rev2-3] Juruena MF, de Sena EP, de Oliveira IR (May 2011). "Sertindole in the management of schizophrenia". Journal of Central Nervous System Disease. 3: 75–85. doi:10.4137/JCNSD.S5729. PMC 3663609. PMID 23861640.

[1]

[2]

[3]